Keyword Analysis & Research: checkmate 274
Keyword Research: People who searched checkmate 274 also searched
Search Results related to checkmate 274 on Search Engine
-
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial
https://www.nejm.org/doi/full/10.1056/NEJMoa2034442
WEBJun 2, 2021 · The CheckMate 274 trial showed a significant and clinically meaningful benefit of adjuvant systemic immunotherapy as compared with placebo, both in the intention-to-treat population and in ...
DA: 69 PA: 32 MOZ Rank: 45
-
Extended CheckMate-274 Data Reinforce the Benefit of Adjuvant …
https://dailynews.ascopubs.org/do/extended-checkmate-274-data-reinforce-benefit-adjuvant-nivolumab-high-risk-muscle
WEBFeb 17, 2023 · In the CheckMate-274 trial that compared adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, the magnitude of benefit observed with the PD-1 inhibitor has remained consistent over time for the primary and secondary endpoints.
DA: 52 PA: 13 MOZ Rank: 56
-
An Investigational Immuno-therapy Study of Nivolumab, …
https://classic.clinicaltrials.gov/ct2/show/NCT02632409
WEBDec 16, 2015 · A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
DA: 4 PA: 31 MOZ Rank: 31
-
Adjuvant Nivolumab versus Placebo in Muscle-Invasive …
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034442
WEBThus, the phase 3 CheckMate 274 trial was conducted to evaluate the efficacy and safety of adjuvant nivolumab, as compared with placebo, in patients with muscle-invasive urothelial carci -
DA: 83 PA: 69 MOZ Rank: 86
-
First results from the phase 3 CheckMate 274 trial of adjuvant
https://ascopubs.org/doi/10.1200/JCO.2021.39.6_suppl.391
WEBMar 2, 2021 · First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). | Journal of Clinical Oncology. Free access. Urothelial Carcinoma. March 02, 2021.
DA: 57 PA: 71 MOZ Rank: 37
-
Checkmate 274 trial: Is Nivolumab the new standard in adjuvant …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555569/
WEBOct 1, 2021 · Checkmate 274 is a phase 3, multicenter, double-blind, randomized controlled trial recently published in the New England Journal of Medicine, comparing nivolumab with placebo in adjuvant setting in patients with muscle-invasive urothelial carcinoma.
DA: 5 PA: 22 MOZ Rank: 38
-
FDA approves nivolumab for adjuvant treatment of urothelial …
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma
WEBFeb 1, 2022 · Nivolumab was investigated in CHECKMATE-274 (NCT02632409), a randomized, double-blind, placebo-controlled trial in patients who were within 120 days of radical resection of UC of the bladder or...
DA: 31 PA: 64 MOZ Rank: 73
-
Adjuvant nivolumab versus placebo following radical surgery
https://pubmed.ncbi.nlm.nih.gov/36300304/
WEBJan 6, 2023 · PMCID: PMC9825712. DOI: 10.1093/jjco/hyac155. Abstract. Background: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant nivolumab over placebo after radical surgery in patients with high-risk muscle-invasive urothelial carcinoma.
DA: 38 PA: 15 MOZ Rank: 48
-
Use of Adjuvant Nivolumab in Patients With Muscle-Invasive …
https://ascopost.com/news/january-2024/use-of-adjuvant-nivolumab-in-patients-with-muscle-invasive-urothelial-carcinoma/
WEBJan 30, 2024 · In the CheckMate 274 trial, researchers randomly assigned patients with muscle-invasive urothelial carcinoma to receive adjuvant nivolumab or placebo. They showed that nivolumab significantly prolonged disease-free survival; however, data on whether or not nivolumab may prolong overall survival are unavailable. Study Methods …
DA: 25 PA: 64 MOZ Rank: 15
-
Extended follow-up results from the CheckMate 274 trial.
https://ascopubs.org/doi/10.1200/JCO.2023.41.6_suppl.LBA443
WEBFeb 21, 2023 · Methods: CheckMate 274 is a phase 3, double-blind trial of adjuvant NIVO versus PBO for high-risk muscle-invasive urothelial carcinoma (MIUC) (bladder, ureter, or renal pelvis) after radical resection. Patients were randomly assigned 1:1 to NIVO 240 mg every 2 wk or PBO for ≤ 1 year of treatment.
DA: 9 PA: 14 MOZ Rank: 65
